FORTBILDUNG: THEMENHEFTTEIL 03 / 2026 KINDERÄRZTE. SCHWEIZ 26 REFERENZEN 1 Meyer Sauteur, P. M. et al. Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study. Lancet Microbe 101019 (2025) doi:10.1016/j.lanmic.2024.101019. 2 Waites, K. B. & Talkington, D. F. Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 17, 697–728 (2004). 3 Meyer Sauteur, P. M., Ramien, M. L. & Theiler, M. Mycoplasma pneumoniae: extrapulmonary manifestations in children with focus on mucocutaneous disease. Pediatr. Infect. Dis. J. 44, e454–e458 (2025). 4 Jain, S. et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N. Engl. J. Med. 372, 835–845 (2015). 5 Meyer Sauteur, P. M. et al. Improved diagnostics help to identify clinical features and biomarkers that predict Mycoplasma pneumoniae community-acquired pneumonia in children. Clin. Infect. Dis. 71, 1645–1654 (2020). 6 Robinson, E. et al. Evolving clinical features of Mycoplasma pneumoniae infections following COVID-19 pandemic restrictions: a retrospective, comparative cohort study. Eur. J. Pediatr. 184, 535 (2025). 7 Meyer Sauteur, P. M. et al. Infection with and carriage of Mycoplasma pneumoniae in children. Front. Microbiol. 7, (2016). 8 Meyer Sauteur, P. M. Diagnose und Therapie der Pneumonie bei Kindern und Jugendlichen. Paediatrica 34, (2023). 9 Meyer Sauteur, P. M. et al. Diagnosis of Mycoplasma pneumoniae pneumonia with measurement of specific antibody-secreting cells. Am. J. Respir. Crit. Care Med. 200, 1066–1069 (2019). 10 Meyer Sauteur, P. M., Trück, J., van Rossum, A. M. C. & Berger, C. Circulating antibody-secreting cell response during Mycoplasma pneumoniae childhood pneumonia. J. Infect. Dis. 222, 136–147 (2020). 11 Harris, M. et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 66 Suppl 2, ii1-23 (2011). 12 Pneumonia: Diagnosis and Management. (National Institute for Health and Care Excellence (NICE), London, 2025). 13 Bradley, J. S. et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin. Infect. Dis. e25-76 (2011). 14 Crokaert, F., Hubloux, A. & Cauchie, P. A Phase I determination of azithromycin in plasma during a 6-week period in normal volunteers after a standard dose of 500mg once daily for 3 days: Clin. Drug Investig. 16, 161–166 (1998). 15 Wagner, K., Imkamp, F., Pires, V. P. & Keller, P. M. Evaluation of Lightmix Mycoplasma macrolide assay for detection of macrolide- resistant Mycoplasma pneumoniae in pneumonia patients. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 25, 383.e5-383.e7 (2019). 16 Kim, K. et al. Global trends in the proportion of macrolide- resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA Netw. Open 5, e2220949 (2022). 17 Hagman, K., Nilsson, A. C., Hedenstierna, M. & Ursing, J. Epidemiology, characteristics, and treatment outcomes of Mycoplasma pneumoniae pneumonia in hospitalized adults: a 5-year retrospective cohort study. Open Forum Infect. Dis. 12, ofaf380 (2025). 18 Tetracyclines. in Red Book: 2024–2027 Report of the Committee on Infectious Diseases (eds Kimberlin, D. W., Banerjee, R., Barnett, E. D., Lynfield, R. & Sawyer, M. H.) 975–976 (American Academy of Pediatrics345 Park Blvd, Itasca, IL 60143, 2024). doi:10.1542/ 9781610027373-S4_001_003. 19 H. Cody Meissner. When can doxycycline be used in young children? Am. Acad. Pediatr. News https://publications.aap.org/ aapnews/news/14899/When-can-doxycycline-be-used-in-youngchildren (2020). 20 Meyer Sauteur, P. M. et al. Doxycycline’s stains. Arch. Dis. Child. 111, 456–456 (2026). 21 Gardiner, S. J., Gavranich, J. B. & Chang, A. B. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst. Rev. 1, CD004875 (2015). 22 Williams, D. J. et al. Effectiveness of ß-Lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia. JAMA Pediatr. 171, 1184–1191 (2017). 23 Biondi, E. et al. Treatment of Mycoplasma pneumonia: a systematic review. Pediatrics 133, 1081–1090 (2014). 24 Meyer Sauteur, P. M. et al. A randomized controlled non- inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community- acquired pneumonia: trial protocol for the MYTHIC Study. Trials 25, 655 (2024).
RkJQdWJsaXNoZXIy MjYwNzMx